Class Action Lawsuit List: Active Cases & Payouts 2026

Quick Answer
– The 2026 class action lawsuit list spans pharmaceutical injuries, data breaches, product liability, consumer fraud, and securities violations, with hundreds of active cases across federal and state courts.
– Eligibility depends on case type: generally, you must have purchased a product, used a service, or suffered a documented injury tied to the named defendant's conduct during a specific date range.
– Individual payouts range from $15 to $25 in consumer product settlements to $100,000 or more in serious personal injury mass tort cases resolved under the class action framework.

Case Snapshot

Hundreds of class action lawsuits are actively accepting claims in 2026, and the stakes across case categories have never been higher. A single MDL settlement fund can exceed $1 billion, yet the average class member collects far less than that figure suggests, because distribution depends heavily on case category, injury severity, and how many claims are filed.

This class action lawsuit list covers the major active categories. It identifies which courts are presiding, what the cases are actually worth at the individual level, and which attorney practice areas manage these claims.

Another useful guide: Minecraft Lawsuit 2026: Class Action Claims Explained

Two things separate a legitimate active case from a dormant one in 2026: class certification status and the presence of an active claims administrator. Both details are covered for each category below.

Readers who find a matching case in this list should document their purchase records, medical records, or breach notification letters before contacting an attorney. That documentation changes the trajectory of a claim.

The 2026 Class Action Lawsuit List: What It Covers and Why It Matters Now

The 2026 class action lawsuit list is not a single document filed in any one court. It refers to the aggregate body of active, certified, or recently settled class actions pending across U.S. federal and state courts at any given time in 2026.

As of early 2026, the Judicial Panel on Multidistrict Litigation (JPML) is overseeing more than 70 active MDL proceedings, many of which originated as or have absorbed related class action filings. Federal dockets in the Northern District of California, Southern District of New York, District of New Jersey, and Northern District of Illinois carry the heaviest concentration.

State-level class actions run parallel in California, Florida, New York, Illinois, and Texas under their own civil procedure rules, some of which offer stronger remedies than federal Rule 23 actions.

Key categories on the 2026 list:

• Pharmaceutical and medical device injury cases
• PFAS and environmental contamination cases
• Data breach and consumer privacy cases
• Consumer product fraud cases
• Securities and investor fraud cases
• Employment and wage theft cases

*Attorney Insight: Attorneys handling class action intake in 2026 report that pharmaceutical and data breach inquiries now account for the largest share of new case evaluations, driven partly by broad media coverage of ongoing MDL proceedings.*

Active Class Action Lawsuits 2026: The Cases Moving Through Courts Right Now

Active class action lawsuits in 2026 are cases where litigation is ongoing, meaning the case has either been filed and is awaiting certification, has been certified and is in discovery or trial preparation, or is in active settlement negotiations.

Several high-profile MDLs reached critical litigation milestones entering 2026. The 3M AFFF (firefighting foam) MDL 2873, pending in the District of South Carolina before Judge Richard Gergel, has processed bellwether trials and moved toward a broad settlement framework involving the municipal water supply contamination track. The Philips CPAP/BiPAP MDL 2903, pending in the Western District of Pennsylvania before Judge Joy Flowers Conti, is in active settlement administration for the device replacement track while personal injury claims continue in litigation.

Active MDL status table — 2026:

*Attorney Insight: Attorneys handling MDL intake point to MDL 2974 (Depo-Provera) as one of the fastest-growing new dockets in 2026, with several thousand cases already filed and class certification briefing expected mid-year.*

Open Class Action Settlements 2026: Which Cases Are Paying Out

Open class action settlements in 2026 are cases where a settlement agreement has been reached and approved by the court, and a claims administrator is currently accepting submissions from eligible class members.

These are the cases where action is most time-sensitive. Once a claims deadline passes, even a valid claim is barred.

Open settlements currently in claims administration (2026):

These figures are drawn from publicly filed settlement documents and court-approved notices. Individual recovery amounts depend on claim volume and injury tier placement within each settlement structure.

*Attorney Insight: Attorneys advising class members note that the per-claimant figure in most consumer settlements drops significantly when claims volume is high, which is why the initial fund size rarely predicts what an individual will actually receive.*

Pharmaceutical Class Action Lawsuits 2026

Pharmaceutical class action lawsuits in 2026 span injury claims tied to prescription drugs, over-the-counter medications, and biologics where manufacturers allegedly failed to warn patients or physicians of known risks.

The most consequential pharmaceutical litigation in 2026 centers on Depo-Provera (medroxyprogesterone acetate), manufactured by Pfizer. MDL 2974 is pending in the Northern District of California. The central allegation is that long-term use of the injectable contraceptive is linked to an elevated risk of meningioma (a type of brain tumor). The MDL was established in late 2024 and is accepting new case filings through 2026.

Separately, litigation over Ozempic, Wegovy, and similar GLP-1 receptor agonists has consolidated under MDL 3080 in the Eastern District of Pennsylvania. The core claims involve gastroparesis and bowel obstruction injuries. As of early 2026, the case is in active discovery with bellwether selection anticipated later in the year.

Pharmaceutical cases — 2026 litigation calendar:

*Attorney Insight: Attorneys handling pharmaceutical injury intake in 2026 emphasize that Depo-Provera and GLP-1 cases are at early enough stages that new clients can still be added to the docket, whereas some older pharmaceutical MDLs have effectively closed to new filings.*

Litigation Watch: The Depo-Provera and Ozempic MDLs represent the two largest pharmaceutical dockets entering 2026, both still accepting new case filings with class certification determinations pending.

Product Liability Class Action Lawsuits 2026

Product liability class actions in 2026 cover defective consumer products, vehicles, appliances, medical devices, and industrial equipment where design defects, manufacturing flaws, or inadequate warnings caused harm at scale.

The Philips CPAP and BiPAP recall remains one of the most active product liability MDLs in federal court. MDL 2903, before Judge Conti in the Western District of Pennsylvania, addresses injuries tied to the degradation of polyester-based polyurethane foam used in recalled sleep apnea devices. Personal injury claims involving lung cancer, respiratory disease, and other cancers are in active litigation. The device replacement class track reached a settlement; the injury track has not.

Vehicle-related product liability class actions in 2026 include ongoing litigation over defective airbag inflators (post-Takata remediation claims), Ford Bronco transmission defects, and Toyota hybrid battery degradation, all at various certification stages in federal district courts.

Product liability case tracker — 2026:

*Attorney Insight: Attorneys in product liability practices note that Philips CPAP personal injury claimants who documented their device model and serial numbers before returning units under recall have significantly stronger file positions than those who did not.*

Data Breach Class Action Lawsuits 2026

Data breach class action lawsuits in 2026 are filed under consumer protection statutes, state data privacy laws, and negligence theories when companies fail to protect personal information and that failure results in unauthorized access at scale.

The AT&T data breach, disclosed in 2024, exposed the records of approximately 73 million customers, including Social Security numbers, account passcodes, and contact data. A class action settlement was reached, with the fund approximated at $13 million and a claims period open in early 2026. Affected customers who received breach notification letters are the primary eligible class.

The National Public Data breach of 2024, which reportedly exposed 2.9 billion personal records, generated multiple class actions filed in the Southern District of Florida. Those cases entered federal court consolidation discussions in late 2024 and are expected to reach certification proceedings in 2026.

Data breach class actions — 2026 status:

*Attorney Insight: Attorneys handling data breach class actions in 2026 note that the Change Healthcare breach may produce the most consequential healthcare privacy settlement in federal history, given the volume of medical records exposed.*

Litigation Watch: The Change Healthcare breach involving UnitedHealth Group and the National Public Data breach are the two data breach actions most likely to produce significant recoveries for class members in 2026, assuming certification proceeds on current timelines.

Consumer Protection Class Action Lawsuits 2026

Consumer protection class action lawsuits in 2026 are brought under state consumer fraud acts, the FTC Act, and related statutes when companies engage in deceptive advertising, hidden fees, auto-enrollment schemes, or false labeling.

Major consumer protection class actions active in 2026 include litigation targeting subscription cancellation practices across streaming and software platforms, junk fee disclosures in hotel, rental car, and ticketing sectors, and false "natural" or "organic" food labeling claims.

The FTC's enforcement actions in 2023 and 2024 against companies using dark-pattern cancellation flows opened the litigation door for private class actions in 2025 and 2026. Several cases are pending in the Northern District of California and Southern District of New York.

Consumer protection class actions — 2026:

Illinois Biometric Information Privacy Act (BIPA) class actions have produced some of the largest per-person statutory damages awards in consumer protection history, with settlements in the $100 million range for large employers.

*Attorney Insight: Attorneys handling consumer protection class actions report that BIPA litigation in Illinois remains the single most active area of statutory consumer class action practice, with new employer-defendant cases filed weekly in the Northern District of Illinois.*

Securities Class Action Lawsuits 2026

Securities class action lawsuits in 2026 are brought under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, Rule 10b-5, and the Private Securities Litigation Reform Act (PSLRA), typically alleging that a company or its executives made material misstatements that inflated share prices.

Securities class actions follow a different procedural path than consumer or personal injury class actions. A lead plaintiff, typically an institutional investor with the largest financial loss, is appointed by the court to represent the class. Individual retail investors are class members automatically unless they opt out.

Active securities class actions — 2026:

The PSLRA requires a 90-day lead plaintiff motion period after the public notice of the lawsuit. Investors who held shares during the "class period" — the window of alleged misstatements — are typically eligible to file lead plaintiff motions or participate passively as class members.

*Attorney Insight: Attorneys handling securities class actions note that SPAC-related litigation has become one of the fastest-growing subcategories in 2025 and 2026, as de-SPAC transactions from 2020 to 2022 face mounting scrutiny over disclosure accuracy.*

Litigation Watch: Securities class actions against Boeing, several EV-sector companies, and multiple post-SPAC merger entities are advancing through federal courts in 2026, with institutional investor lead plaintiff appointments driving litigation pace.

MDL Lawsuits 2026: How Multidistrict Litigation Differs From Standard Class Actions

MDL lawsuits in 2026 are not technically class actions in the Rule 23 sense, but they function as a consolidated litigation vehicle for large numbers of individually filed cases sharing common facts, typically pharmaceutical injuries, product defects, or industrial contamination.

The JPML transfers related federal cases to a single transferee court for coordinated pretrial proceedings. Each plaintiff retains an individual case. This is the critical distinction from a class action, where one judgment binds all members.

On a related note, check out Minecraft Lawsuit 2026: Class Action, Claims and Payouts

Active MDLs — 2026 summary:

The J&J talc litigation (MDL 2738) has been complicated by Johnson & Johnson's use of a Texas Two-Step bankruptcy strategy, which federal appellate courts addressed in 2024. The litigation status of that docket in 2026 depends on the outcome of those bankruptcy proceedings.

*Attorney Insight: Attorneys who practice in MDL proceedings note that clients often do not realize they are filing an individual case within a coordinated MDL, not joining a class — meaning their individual recovery depends on their own injury tier, not a shared per-claimant formula.*

Class Action Lawsuit Eligibility Requirements

Class action lawsuit eligibility is governed by Rule 23 of the Federal Rules of Civil Procedure, which requires that four threshold criteria be met before a court will certify a class: numerosity, commonality, typicality, and adequacy of representation.

For individual class members, eligibility is simpler. The class definition — established in the court's certification order — specifies who qualifies. It typically includes:

Standard eligibility criteria by case type:

The class period dates are among the most critical eligibility factors. Purchasing a product one day outside the defined window can exclude an otherwise valid claim.

*Attorney Insight: Attorneys reviewing class action eligibility in pharmaceutical and environmental cases consistently identify incomplete or missing medical documentation as the primary reason for claim denial at the settlement administration stage.*

Class Action Payout Amounts: What Individual Class Members Actually Receive

Class action payout amounts vary across an extraordinarily wide range depending on case type, injury severity, settlement fund size, and total number of claims submitted.

The gap between headline settlement figures and individual recovery is one of the most misunderstood aspects of class action litigation. A $100 million settlement split among 5 million class members produces $20 per person, before attorneys' fees. Attorneys' fees in class actions typically range from 25% to 33% of the total fund under the percentage-of-fund method used by most federal courts.

Estimated payout ranges by case type — 2026:

These figures are approximations drawn from publicly available settlement data and court-filed distribution plans. Individual recovery is calculated by the claims administrator according to the court-approved plan of allocation.

*Attorney Insight: Attorneys advising clients on settlement acceptance recommend comparing the offered settlement amount against what a retained personal injury attorney could recover in an individual lawsuit before signing a release — especially in pharmaceutical injury cases where individual case value may far exceed the class settlement tier.*

Litigation Watch: Per-claimant payouts in consumer data breach cases remain low where documented harm is absent, while pharmaceutical and mass tort claimants with strong medical records are recovering amounts that dwarf the consumer class action averages.

Class Action Lawsuit Filing Deadline 2026: Critical Dates Across Active Cases

Class action lawsuit filing deadlines in 2026 take two forms: claim submission deadlines for already-settled cases, and statutes of limitations for cases not yet filed.

Missing either deadline can permanently bar recovery. Claims deadlines in settled cases are set by court order. Statutes of limitations for new cases vary by state and case type, ranging from one year (some state consumer fraud claims) to six years (some contract-based consumer claims).

2026 filing deadlines — confirmed and approximate:

The statute of limitations for pharmaceutical injury cases is typically two years from discovery of the injury's cause, not two years from when the drug was taken. Many claimants who used Depo-Provera years ago may still have valid claims if diagnosed recently.

*Attorney Insight: Attorneys handling pharmaceutical MDL intake consistently cite the discovery rule as the most misunderstood deadline concept — claimants who stopped using a drug in 2019 may still have a viable 2026 filing window if the causal link between the drug and their diagnosis was not established until recently.*

Mass Tort vs. Class Action Lawsuit: The Legal Distinction That Affects Your Recovery

Mass tort and class action are not interchangeable terms, and the distinction directly affects how much an individual plaintiff can recover and what control they have over their own case.

A class action under Rule 23 binds all class members to a single judgment or settlement unless they affirmatively opt out. One named plaintiff (or a small group) represents thousands or millions of others. Recovery is typically uniform within tiers.

A mass tort involves thousands of individually filed lawsuits, often consolidated into an MDL, where each plaintiff pursues their own case. Recovery is individualized based on specific injury, exposure, and damages.

Comparison table:

The practical result: a consumer overcharged $30 on a subscription is best served by a class action. A patient who developed meningioma after Depo-Provera use is best served by an individual mass tort filing within MDL 2974.

*Attorney Insight: Attorneys handling intake for pharmaceutical injury cases in 2026 consistently advise that clients with serious documented injuries opt out of any class settlement that undervalues their individual harm, particularly when individual MDL case resolution is likely to produce higher recovery.*

How to Join a Class Action Lawsuit

Joining a class action lawsuit depends entirely on whether you are within the certified class definition, and whether the case requires active participation or automatic inclusion.

For most consumer and data breach class actions, membership is automatic if you fall within the class definition. You do not need to file anything. You will receive a class notice, typically by email, postcard, or publication, explaining your rights and the claims process.

Steps to participate in an active class action — 2026:

• Step 1: Confirm you fall within the class definition (date range, product, geographic area, account type).
• Step 2: Review the class notice, which identifies the settlement fund, per-claimant estimate, claims deadline, and opt-out deadline.
• Step 3: Submit a claim form to the designated claims administrator before the published deadline.
• Step 4: If the per-claimant amount is substantially lower than your actual loss, consult a class action attorney about opting out and filing individually.
• Step 5: For pharmaceutical or serious injury cases not yet settled, retain an attorney and file an individual complaint that may be consolidated into the relevant MDL.

The opt-out right is among the most valuable and least-used protections in class action law. Opt-out deadlines are typically 30 to 60 days after notice is sent.

*Attorney Insight: Attorneys evaluating opt-out decisions note that the calculus depends on whether individual litigation is economically viable — for small-dollar consumer claims, opting out to sue alone rarely makes financial sense, but for serious injury claims, opt-out is frequently the correct decision.*

Litigation Watch: For pharmaceutical and mass tort cases in 2026, the distinction between joining a class settlement automatically and filing an individual MDL case is the single most financially consequential decision a potential claimant can make.

What Type of Lawyer Handles Class Action Lawsuits

The type of lawyer who handles class action lawsuits depends on the case category, because different class action subspecialties require entirely different litigation skill sets, expert networks, and court relationships.

Attorney type by case category:

Attorney fees in class actions and mass torts are almost universally contingency-based, meaning no upfront payment from the client. Class counsel fees are approved by the court as part of the settlement. Individual mass tort attorneys typically take 33% to 40% of individual recovery.

*Attorney Insight: Attorneys who specialize in mass torts and MDL litigation maintain relationships with coordinating plaintiff steering committees — which is why retaining an attorney with active MDL experience, rather than a general practice attorney, materially affects case positioning.*

Class Action Lawsuit Status by State: Where Cases Are Concentrated

Class action lawsuit status varies by state because both federal and state court class actions are active simultaneously, and state procedural rules, statutory damages, and judicial posture differ significantly across jurisdictions.

California, Illinois, and New York account for the largest volume of state-level class action filings. California's Unfair Competition Law (UCL), Consumers Legal Remedies Act (CLRA), and False Advertising Law (FAL) provide some of the broadest private right of action in the country. Illinois BIPA creates strict liability for biometric data violations with statutory damages of $1,000 to $5,000 per violation.

This may also interest you: AT&T Data Breach Lawsuit 2026: Claims & Settlement Guide

State class action landscape — 2026:

Federal courts in the Northern District of California (San Jose and San Francisco divisions) receive more technology and consumer protection class action filings than any other single district in the country.

*Attorney Insight: Attorneys filing consumer class actions in 2026 frequently evaluate whether to file in federal court under CAFA or remain in state court, because state courts in California and Illinois sometimes offer stronger remedies and lower procedural hurdles than the federal class certification standard.*

How Long Does a Class Action Lawsuit Take to Resolve

How long a class action lawsuit takes depends primarily on whether the case settles early, proceeds to trial, or gets bogged down in appellate certification disputes.

Early consumer fraud settlements — cases where liability is clear and individual damages are small — can resolve in 18 to 36 months from initial filing to distribution. Complex pharmaceutical MDLs can take 5 to 10 years or longer from first filing to full distribution.

Class action timeline — typical phases:

The total elapsed time from first filing to a check in a class member's hands is rarely less than three years for any substantive class action. For MDL pharmaceutical cases, seven to ten years is not uncommon.

*Attorney Insight: Attorneys advising pharmaceutical injury clients on timeline expectations note that MDL bellwether trials — which test a handful of representative cases to assess settlement value — are often the turning point that accelerates global resolution, as they were in the 3M earplug and Roundup litigations.*

Litigation Watch: Class action timelines in 2026 are being compressed in some consumer cases by early-stage mediation pressure from defendants seeking to avoid certification, while pharmaceutical MDL timelines remain extended by scientific causation disputes that require years of expert development.

Largest Class Action Settlements in US History: The Cases That Set the Scale

The largest class action settlements in U.S. history provide the benchmark against which 2026 litigation is measured — and they reveal how wide the range of outcomes actually is.

Top confirmed class action and mass tort settlements (historical record):

The scale of the opioid litigation — $26 billion spread across state and local government plaintiffs — represents the largest mass tort resolution in U.S. history outside of tobacco. These figures set the financial floor against which active 2026 MDL settlement negotiations are measured.

*Attorney Insight: Attorneys with experience in large MDL resolutions note that the opioid and 3M earplug settlements fundamentally changed how defendants approach early global resolution discussions, making 2026 a more settlement-active environment than any prior period in MDL history.*

Frequently Asked Questions

What is the current class action lawsuit list for 2026?

The 2026 class action lawsuit list includes hundreds of active cases across pharmaceutical injury, data breach, consumer fraud, product liability, securities fraud, and employment categories.

The most significant active MDLs include Depo-Provera (MDL 2974), Ozempic GI injury (MDL 3080), Philips CPAP (MDL 2903), and 3M AFFF contamination (MDL 2873).

Cases are pending in federal courts including the N.D. Cal., W.D. Pa., E.D. Pa., D.S.C., and N.D. Ill.

How do I know if I qualify for a class action lawsuit?

Eligibility is defined by the court-approved class definition, which specifies the product, date range, geographic area, or type of harm that qualifies.

For settled cases, you will receive a class notice; for active cases, an attorney can review your records against the current class definition or MDL intake criteria.

Missing documentation — purchase receipts, medical records, breach notifications — is the most common barrier to eligibility confirmation.

How much money can I get from a class action lawsuit?

Individual class action payouts range from under $10 in high-volume consumer product cases to $500,000 or more in serious pharmaceutical or mass tort injury cases.

The amount depends on the total settlement fund, number of claims submitted, and your injury tier within the court-approved plan of allocation.

Pharmaceutical and mass tort MDL cases, where individual recovery is not divided among millions of claimants, consistently produce higher individual outcomes than consumer class actions.

What is the difference between a class action lawsuit and a mass tort?

A class action binds all members to one judgment under Rule 23, with recovery shared across the class; a mass tort involves individual lawsuits consolidated for efficiency in an MDL, with each plaintiff keeping their own case.

The key practical difference is control: class members are in automatically and receive a formula-based payment, while mass tort plaintiffs retain individual control over their case and can negotiate individual settlements.

Serious personal injury claimants almost always receive higher recovery through individual mass tort filings than through class settlement participation.

What type of lawyer handles class action lawsuits?

The correct attorney specialty depends entirely on the case category: mass tort attorneys handle pharmaceutical and product injury MDLs; consumer protection attorneys handle false advertising and fraud class actions; securities litigation attorneys handle investor fraud under PSLRA.

All of these attorneys work on contingency, meaning no upfront legal fees.

Retaining an attorney who specifically practices in the relevant MDL or class action category materially affects case outcome.

How long does it take for a class action lawsuit to settle?

Consumer class actions typically resolve in 18 to 36 months; pharmaceutical and environmental MDLs routinely take 5 to 10 years from initial filing to final distribution.

Bellwether trial results in MDLs are typically the event that triggers large-scale global settlement negotiations, as demonstrated by the Roundup and 3M earplug litigations.

Individual claimants within MDLs may resolve their cases on individualized timelines that differ from the overall MDL duration.

What the 2026 Litigation Calendar Means for Potential Claimants

The active class action lawsuit list in 2026 is not a static document. Cases move through certification, bellwether trials, settlement negotiations, and claims administration on rolling timelines that create distinct windows for participation.

The most time-sensitive actions in 2026 are those with confirmed claims deadlines in active settlement administration — AT&T breach and Google location data are the clearest examples. Pharmaceutical MDLs including Depo-Provera and Ozempic are still accepting new individual filings, but those windows narrow as litigation matures.

Any reader who identifies a matching case in this list should gather relevant documentation and consult an attorney who specifically practices in that litigation area. The type of attorney matters as much as the timing.

Before you go further, consider reading GOLO Lawsuit 2026: Claims, Settlement & Who Qualifies